NuVision Biotherapies is delighted to announce that Roger Teasdale has joined the Board as an Independent Non-Executive Director.
Roger enjoyed a successful 25 year career at Smith & Nephew, the FTSE 100 Medical device business focused on the Advanced Wound Management and Advanced Surgical Devices sectors with sales in excess of $4.8bn and operations in 120 countries.
For his last 5 years at Smith & Nephew, Roger was President of the Global Advanced Wound Management business with sales of $1.4bn and 4000 people in 80 countries. Roger gained a proven international track record in driving revenue and profit growth in the medical device industry. His most recent role is Group Managing Director at Premier Technical Services Group, a listed niche specialist service provider. Roger is a qualified Chartered Accountant and holds a BA in Accounting and Management Control.
Roger’s knowledge and expertise of the wound care market will be pivotal in guiding NuVision as we embark of on a trajectory to develop Omnigen for treatment of Diabetic Foot Ulcers as well as other wound care applications in the near future. A MediLink/AHSN East Midlands-funded randomised clinical trial is about to start at Derby Hospital, lead by Professor Fran Game, whereby Omnigen will be used treat patients suffering with diabetic foot ulcer. It is hoped that the outcomes of this, coupled with Roger’s understanding of the market, will aid in ensuring that not only patients with ocular surface indications benefit from Omnigen but patients with chronic wounds are also treated.
Roger has extensive experience in many further areas such as sales, marketing, business development, operations, R&D and executive leadership. His background ensures he is skilled in driving company growth and success. Such knowledge will be hugely valuable for NuVision as he guides our board in making important decisions and shaping the company in strategic planning as it grows and expands.
CEO of NuVision Andrew Hopkinson commented “We are extremely excited to have Roger join the team. Roger has unparalleled expertise in the wound care arena that will be invaluable to NuVision’s development of Omnigen for Advanced Wound Management. This is timely with the first clinical trial of Omnigen treatment of Diabetic Foot Ulcers, about to start in Derby Hospital, next month.”
Roger said of the appointment “I am delighted to be joining NuVision at such an exciting time in the Company’s evolution, as we share a passion and optimism in the practice of Wound management to overcome the intractable problem of chronic wounds. Over my 25 years with Smith & Nephew and more recently, I have reviewed many innovative Wound Care products and I am impressed with the tremendous potential of the NuVision technologies which are proven in their ability to heal ocular surface and hard to heal wounds. I look forward to helping the Board and the wider company with their successful commercialisation.”